Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC-391 + pembrolizumab in advanced NSCLC
NCT05860296Phase 2Terminated
- Sponsor
- SignalChem Lifesciences Corporation
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of slc-391 in non-small cell lung cancer (NSCLC), sponsored by SignalChem Lifesciences Corporation. Started May 2023; status: terminated.
02
Drugs
slc-391
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05860296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860296.